Digital Fitness Market Potential Risks and Comprehensive Competitive Strategy Analysis in Different Fields, Report 2020 to 2025

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

“Digital Fitness Market” research report offers the breakdown of the industry by market size, rate of development, key companies, counties, product selections and application. The Digital Fitness Market Report delivers current state, openings, limits, drivers and also the evolution forecasts of the market by 2025. Profound investigation about Digital Fitness market standing, enterprise competition outline, welfares and drawbacks of enterprise stock, Digital Fitness industry development trends, regional industrial layout features and economics policies, industry News and Strategies by Regions has additionally been enclosed.

Get a Sample Copy of the Report at- https://www.industryresearch.co/enquiry/request-sample/16706715

In Regional Analysis, the Digital Fitness market is also categorised into North America, Europe, China, Japan, the middle East, India, South America, Others. North America, Europe is expected to account for a distinguished share, in terms of price and extent, of the Digital Fitness market throughout the forecast length. The Digital Fitness market within the Asia Pacific is projected to extend throughout the forecast period. Evolving markets that include China and Asian country are expected to play a significant position within the boom in producing the surrounding area.

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2025

To Understand the Impact of COVID-19 on Digital Fitness Market: – https://www.industryresearch.co/enquiry/request-covid19/16706715

Digital Fitness market report provides in-depth data about company Profiles, Digital Fitness launching and Market Positioning, their Production, Value, Price, ratio and Target Customers. Research report contains data about following major players in Digital Fitness market, which strategically profile the key players and comprehensively analyse their growth strategies and market segmentation:

Key players in the global Digital Fitness market covered in report:

● Garmin, Ltd ● Samsung Electronics Co. Ltd ● Casio ● Fitbit, Inc ● Adidas AG ● Huawei ● Fossil ● Xiaomi ● TicWatch ● Apple, Inc

On the basis of types, the Digital Fitness market from 2015 to 2025 is primarily split into:

● Smartwatches ● Fitness Wristbands ● Smart Clothing ● Smart Shoes ● Others

On the basis of applications, the Digital Fitness market from 2015 to 2025 covers:

● Fitness ● Sports

Inquire or Share Your Questions If Any Before the Purchasing This Report- https://www.industryresearch.co/enquiry/pre-order-enquiry/16706715

Digital Fitness Market Report Scope:

The In-depth industry chain includes analysis value chain analysis, porter five forces model analysis and cost structure analysis. This Digital Fitness Market report describes present situation, historical background and future forecast. It Comprehensive data showing Digital Fitness sale, consumption, trade statistics, and prices in the recent years are provided. The Digital Fitness report indicates a wealth of information on Digital Fitness vendors. Digital Fitness Market forecast for next five years, including Market volumes and prices is also provided. Raw Material Supply and Downstream Consumer Information is also included.

At last, report on Digital Fitness Market is a comprehensive analysis of the Market providing

Read more

As rich countries hoard potential coronavirus vaccine doses, rest of world could go without

As a result, relatively wealthy nations will likely be able to vaccinate their entire populations, with billions of others relegated to the back of the line. People in low-income countries could be waiting until 2024.

These deals between countries and drug manufacturers, known as advance purchase agreements, are undermining a World Health Organization-linked initiative to equitably distribute vaccines, the study suggests.

“Where we are headed is a situation where high-income countries have enough, and low-income countries just don’t,” said Andrea Taylor, the lead researcher.

Since the vaccine race got underway, experts have warned of the dangers of “vaccine nationalism” and calling for a cooperative approach to vaccine development and distribution.

More than 150 countries, representing a large share of the world’s population, have signed on to participate in the Covid-19 Vaccines Global Access Facility, or Covax, which aims to develop and equitably distribute $2 billion in doses of a vaccine by the end of next year.

Under the plan, both rich and poor countries pool money to offer manufacturers volume guarantees for potential vaccines. The idea is to discourage hoarding and focus on vaccinating high-risk people in every participating country first.

Many wealthy players, including the European Union, Canada and Japan, joined the initiative. But most are backing Covax while also cutting deals directly with manufacturers.

The researchers found that Canada and the United Kingdom have already reserved more than enough potential vaccines to cover their entire populations. The E.U. has also secured hundreds of millions of doses.

These deals make sense from a country perspective, but they undermine cooperative efforts to secure enough doses, particularly for low-income countries, experts said.

“The more that countries hedge their bets and work outside of Covax, the harder it is for Covax to actually deliver on its promises,” said Suerie Moon, co-director of the Global Health Center at the Graduate Institute of International and Development Studies in Geneva.

Rich countries, she said, “are eating up all the supply before Covax can take a nibble.”

The United States did not join Covax, in part because the Trump administration did not want to work with the WHO. The Duke analysis found that the U.S. already has agreements to buy enough doses to cover 139 percent of its population — and could eventually control 1.8 billion doses, or roughly a quarter of the world’s “near-term” supply.

Middle-income countries are also reserving doses. Brazil and India already have secured the rights to enough vaccines to cover about half of their populations, the study noted.

Most low-income countries, by contrast, have little choice but to rely on Covax, which must compete with big players to secure access to vaccines.

Taylor, the lead researcher, stressed that the study offers a “snapshot” of where things stand, not a definitive prediction. Access to vaccines depends in large part on which vaccines prove safe and effective — and that is still very much up in the air.

Another critical question is capacity: How many coronavirus vaccines can the world make in a

Read more

More Potential Help for Chronic Hand Eczema

Two different Janus kinase (JAK) inhibitors, one systemic and the other topical, showed activity in preliminary clinical trials of difficult-to-treat chronic hand eczema.

The oral multitargeted drug gusacitinib reduced the target lesion symptom score (TLSS) by as much as 70% at 16 weeks, and almost a third of patients treated with the higher of two doses achieved Physician Global Assessment (PGA) of 0-1 (clear/nearly clear) at the same time point. Adverse events across the range of doses evaluated were mostly sporadic and mild or moderate in severity, reported Howard Sofen, MD, of Dermatology Research Associates in Los Angeles, during the European Academy of Dermatology and Venereology Virtual Congress.

“Gusacitinib showed rapid efficacy in moderate to severe chronic hand eczema,” said Sofen. “The 80-mg dose met the primary endpoint of percent reduction in the modified TLSS at week 16. Rapid and significant improvement in PGA 0-1 was observed versus placebo with 80 mg. There was dose-dependent and rapid improvement in pruritus. Gusacitinib was well tolerated, and the safety has been consistent across studies involving more than 350 patients.”

In another study, as many as 37% of patients treated with topical delgocitinib met criteria for Investigator’s Global Assessment (IGA) of treatment success at 16 weeks. Patients treated with the two highest concentrations had statistically greater improvement at 4 to 6 weeks and maintained the difference to the end of the study, reported Margitta Worm, MD, of Charite Hospital in Berlin.

Multitargeted Oral Drug

Chronic hand eczema is a complex disease that affects about 7 million people in the U.S. The disease has a multifactorial etiology and pathogenesis that includes genetics, atopy, contact allergens, and irritating substances, said Sofen. Gusacitinib inhibits JAK1, JAK2, JAK3, TYK2, and SYK to target TH1 and TH2 pathways, TH17 and TH22 pathways, and SYK-mediated interleukin-17 signaling in keratinocytes.

Sofen reported findings from the first part of a phase IIb trial involving 105 patients with chronic hand eczema. The patients were randomized to placebo or one of two doses of gusacitinib. Randomized treatment continued for 16 weeks, at which point placebo-treated patients could switch to the higher dose of gusacitinib for continued treatment. The primary endpoint was percent change in the modified TLSS.

The study population had a mean baseline mTLSS of 13 and a mean baseline hand eczema severity index (HECSI) score of 63; 39% of the patients had a baseline PGA score of 3.

The 16-week results showed that patients allocated to the higher dose (80 mg) of gusacitinib had a 69.5% reduction in mTLSS, as compared with 49% of patients in the 40-mg group, and 33.5% of those assigned to placebo. Both gusacitinib groups had significantly greater improvement in mTLSS compared with placebo by week 2 (P<0.005), and patients in the higher-dose arm maintained that difference to 16 weeks.

The proportion of patients who achieved PGA 0-1 status by week 16 was 31.3% in the gusacitinib 80-mg arm, 21.25% in the 40-mg arm, and 6.3% in the placebo group. Significantly more patients in both

Read more

Miniature organs help test potential coronavirus drugs; GI symptoms linked to severe COVID-19

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Miniature lungs, colons help test COVID-19 treatments

Tiny organ-like structures grown in the laboratory to behave like human lungs and colons can be used to rapidly screen drugs and identify those with potential as COVID-19 treatments, researchers reported on Wednesday in Nature. Compared with traditional pre-clinical approaches, in which drugs are tested in cells from monkeys or from human cancer patients, these so-called organoids more faithfully mimic the complex cell types and structure of human tissues, according to Dr. Shuibing Chen and Dr. Robert Schwartz of Weill Cornell Medicine in New York. Their team developed organoids containing types of lung and colon cells that are known to become infected in people with COVID-19. In collaboration with teams at Columbia University and Icahn School of Medicine at Mount Sinai, they screened 1,200 FDA-approved drugs and found three that showed activity against the novel coronavirus, including the cancer drug imatinib, sold as Gleevec by Novartis. It is currently being tested in four different COVID-19 clinical trials. (https://go.nature.com/34CLDtS)

GI symptoms linked with more severe COVID-19

Gastrointestinal (GI) symptoms are associated with more severe COVID-19 and worse outcomes, two research teams reported on Monday, a reversal of earlier data that suggested the opposite was true. One team reviewed 38 earlier studies of a total of more than 8,400 patients and found those with diarrhea were 63% more likely to develop severe COVID-19. Dr. Subash Ghimire of Guthrie Robert Packer Hospital in Pennsylvania suggested that patients with diarrhea may have higher viral loads, which can potentially lead the body to fight back with more severe responses. The other team studied 921 patients and found that the roughly 22% with at least one GI symptom had higher rates of hospital and intensive-care unit admissions and greater need for mechanical breathing assistance. The more GI symptoms patients had, the more their risk for these outcomes increased, Dr. Darbaz Adnan of Rush University Medical Center in Chicago reported. He said doctors evaluating COVID-19 patients need to bear in mind that GI symptoms may signal a markedly higher risk of a worsened disease course. Both studies were presented at the American College of Gastroenterology virtual annual meeting. (https://bit.ly/37OgZQh)

UK population with COVID-19 antibodies is shrinking

A new wave of coronavirus infections has been spreading in the UK, but the proportion of the population there with antibodies to the virus has been shrinking, potentially leaving more people vulnerable, new data show. In a report posted on Tuesday on medRxiv ahead of peer review, scientists at Imperial College London say that while 6% of the population had COVID-19 antibodies around the end of June, that rate fell to just 4.4% in September. Antibodies are not the body’s only line of defense. Also important are immune cells called T cells and B cells that

Read more

U.S. signs deal with Lilly for supply of potential COVID-19 antibody drug

FILE PHOTO: Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake

(Reuters) – The U.S. Government has awarded an initial $375 million contract to drugmaker Eli Lilly and Co LLY.N to secure 300,000 doses of its potential experimental COVID-19 antibody treatment, a drug that has been touted by U.S. President Donald Trump.

Lilly will start delivering the treatment within two months of receiving an emergency use authorization from the U.S. health regulator, the company said.

The U.S. government also has the option to purchase up to an additional 650,000 vials for $812.5 million, the U.S. Department of Health and Human Services said in a statement.

While vaccines are seen critical to ending the pandemic, governments are increasingly looking at effective treatment options to slow the spread of the disease and kick-start economic activity.

The company submitted a request to the U.S. Food and Drug Administration earlier this month for emergency use authorization of the drug to treat mild to moderate COVID-19 patients.

The U.S. government has committed that patients will have no out-of-pocket costs for the medicine, although healthcare facilities may charge a fee for the product’s administration, Lilly said.

The antibody therapy is similar to a drug from Regeneron Pharmaceuticals REGN.O that was given to Trump during his bout with COVID-19.

The treatments belong to a class of drugs called monoclonal antibodies that are manufactured copies of antibodies created by the body to fight against an infection. Lilly’s antibody was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty

Source Article

Read more

Fauci says findings on a potential coronavirus vaccine are expected by early December

Dr. Anthony Fauci

“We will know whether a vaccine is safe and effective by the end of November, beginning of December,” the director of the US National Institute of Allergy and Infectious Diseases said. “The amount of doses that will be available in December will not certainly be enough to vaccinate everybody — you’ll have to wait several months into 2021.”

Speaking to the BBC’s Andrew Marr Show, Fauci added that the vaccination of a “substantial proportion of the population” so there could be a “significant impact on the dynamics of the outbreak” may not be possible until the second or third quarter of 2021.

Pence adviser Marty Obst tests positive for coronavirus

“What I do foresee is that with a successful vaccine and the continuation of some form of public health measures, as we go and progress through the months of 2021, getting towards the third and fourth quarter, we will see a considerable approach towards some form of normality,” Fauci told Marr.

Pressed on whether he believes US President Donald Trump is correct in saying that the United States is “rounding the corner” in the course of the pandemic, Fauci said he believes this is untrue.

“The data speak for themselves,” Fauci said.

“Unfortunately, I am sorry to see what I’m viewing from a distance, what I’m seeing in the UK … after getting hit pretty badly the way we did, you went down to a pretty low level, but now you’re starting to escalate in the same manner that we are here,” he added.

Source Article

Read more

Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies

  • Synairgen’s SNG001 among the many potential treatments and vaccines to be delivered via Aerogen’s aerosol drug delivery system

  • Adds to the thousands of COVID-19 patients already safely and effectively treated with Aerogen’s Solo aerosol drug delivery system in the intensive care unit 1

  • Aerogen technology is featured in guidelines and papers on the treatment of COVID-19 patients across the globe 2,3,4

Aerogen, the global leader in aerosol drug delivery, today announced details of a broad collaborative effort to support pharmaceutical companies from around the world as they work to develop COVID-19 vaccines and treatments. To date, more than ten million patients globally have been treated safely and effectively with Aerogen’s drug delivery technology 1,5–7. As the global scientific community rallies against the pandemic, there has been unprecedented interest in inhaled delivery of antiviral drugs, leading to Aerogen’s involvement in multiple COVID-19 drug development initiatives with leading pharmaceutical companies and prominent academic groups.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022006039/en/

Aerogen Ultra (Photo: Business Wire)

Aerogen’s closed-circuit nebulizer technology, which addresses key concerns around safety and improves patient outcomes5–8, is being used in hospitals across the globe to deliver aerosolized medication to critically-ill ventilated COVID-19 patients1. Aerogen was quick to anticipate the critical role that development of new inhaled drugs will ultimately play in the COVID-19 response, and in March of this year formed a COVID response unit to support projects researching potential treatments and vaccines. This response unit is now working with pharmaceutical companies worldwide to ensure safe delivery of inhaled therapies. Several of these collaborations are already in clinical trials, with others on track to enter studies on moderately and severely ill COVID-19 patients over the weeks and months ahead.

In one such collaboration, Aerogen has signed an agreement with Synairgen plc, a Southampton, UK-based biotechnology company, to provide the market-leading Aerogen® Solo/Ultra nebulizer system for delivery of SNG001 directly into the lungs of COVID-19 patients. SNG001 is an inhaled interferon beta that stimulates the innate immune system. Initial investigation of SNG001 as a potential COVID-19 treatment has been promising – hospitalized patients receiving SNG001 were at reduced risk of developing severe disease and more than twice as likely to recover to the ‘no limitation of activities’ level on the ordinal scale over the course of treatment9,10.

“Aerogen is a highly regarded global company known for providing safe and effective aerosol drug delivery,” said Richard Marsden, CEO of Synairgen. “Ensuring that SGN001 is paired with optimal delivery technology is a vital component of our work to bring this potential treatment to market at scale. Aerogen is our choice because of its proven reputation for drug delivery efficiency and reliability, suitability for use with a wide range of ventilatory support modalities, established high-volume manufacturing and prior regulatory approvals across the globe.”

“In the early days of the pandemic, hospitals were discouraged from using any type of aerosol for COVID-19 treatment – which

Read more

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

  • Roche and Atea partner to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in Phase 2 clinical trials

  • AT-527 has the potential to be the first novel oral antiviral to treat COVID-19 patients outside the hospital setting as well as in the hospital and may also be used in post-exposure prophylactic settings

  • Oral, small-molecule DAAs for COVID-19 patients allow for large-scale manufacturing and facilitate broad patient access

  • If approved, Atea will distribute AT-527 in the United States and Roche will be responsible for global manufacturing and distribution outside the United States

Basel, 22 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in a Phase 2 clinical trial for hospitalised patients with moderate COVID-19. A Phase 3 clinical trial, expected to start in Q1 2021, will explore the potential use in patients outside of the hospital setting. In addition, AT-527 may be developed for post-exposure prophylactic settings.

AT-527, while being a potential oral treatment option for hospitalised patients, also holds the potential to be the first oral treatment option for COVID-19 patients that are not hospitalised.  Additionally, the manufacturing process of small-molecule DAAs allows the ability to produce large quantities of a much needed treatment. If successful, AT-527 could help treat patients early, reduce the progression of the infection, and contribute to decreasing the overall burden on health systems.

The collaboration aims to accelerate the clinical development and manufacturing of AT-527, to investigate its safety and efficacy, and to provide this potential treatment option to patients around the world as quickly as possible. If AT-527 proves safe and effective in clinical trials and regulatory approvals are granted, Atea will be responsible for distributing this treatment option in the U.S, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the United States.

“The ongoing complexities of COVID-19 require multiple lines of defence. By joining forces with Atea, we hope to offer an additional treatment option for hospitalised and non-hospitalised COVID-19 patients, and to ease the burden on hospitals during a global pandemic.” said Bill Anderson, Chief Executive Officer of Roche Pharmaceuticals. “In jointly developing and manufacturing AT-527 at scale, we seek to make this treatment option available to as many people around the world as we possibly can.”

“Roche shares our passion for delivering innovative new medicines to address great unmet medical needs. The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea Pharmaceuticals. “AT-527 is expected to be ideally suited to combat COVID-19 as it inhibits viral replication by interfering with viral RNA polymerase, a key component in the

Read more

HSG Foresees Major Potential Financial Impact on Employed Physician Networks and Medical Groups from 2021 Proposed Medicare Physician Fee Schedule

Healthcare Consultants Urge Hospitals and Health Systems to Start Planning for Impact on Physician Compensation and Medicare Payments for Professional Services.

Neal D. Barker, Partner at HSG, a national healthcare consulting firm is the author of &quot;Changes to the 2021 Medicare Physician Fee Schedule Could Have Major Impact on Physician Compensation.&quot; The article is available for download at the website, hsgadvisors.com.
Neal D. Barker, Partner at HSG, a national healthcare consulting firm is the author of “Changes to the 2021 Medicare Physician Fee Schedule Could Have Major Impact on Physician Compensation.” The article is available for download at the website, hsgadvisors.com.
Neal D. Barker, Partner at HSG, a national healthcare consulting firm is the author of “Changes to the 2021 Medicare Physician Fee Schedule Could Have Major Impact on Physician Compensation.” The article is available for download at the website, hsgadvisors.com.

Louisville, KY, Oct. 21, 2020 (GLOBE NEWSWIRE) — HSG, a national healthcare consulting firm, has published a detailed evaluation of the Centers for Medicare & Medicaid Services (CMS) 2021 Medicare Physician Fee Schedule (MPFS) Proposed Rule, which is scheduled to take effect on January 1, 2021, if approved in the Final Rule. The advisors at HSG believe the proposed changes may have a significant potential impact on physician compensation and urge healthcare executives to start planning for these proposed changes. The agency’s Fee Schedule changes cover everything from Work Relative Value Unit (wRVU) values for specific Current Procedural Terminology (CPT) codes to changes in the scope of practice policies for Advanced Practice Providers (APPs) and changes related to CMS’s quality payment program.

With more than a 10% decrease in the MPFS conversion factor, services that do not have any change in Relative Value Unit values will see a decrease in Medicare payment at the projected rate of more than 10%. The decreased reimbursement will not be fully offset by any reimbursement increases realized through the Quality Payment Program paths. Changes related to outpatient and office evaluation and management (E&M) service code determinations and requirements, along with permanent and temporary additions to telehealth codes, will add to compensation complications. The redefined E&M code selection criteria will now be driven by medical decision making (MDM) or time spent alone – with no direct contribution by history and/or exam elements.

“Assuming these changes are included when the Final Rule is published in early December, many industry organizations, consultancies, and provider advocacy groups are projecting significant increases in provider productivity-based compensation if the providers’ E&M profile remains unchanged,” explained Neal Barker, Partner at HSG. “Ultimately, hospitals and health systems may face a situation in which payments from Medicare will decrease while their physician compensation requirements will significantly increase based on the widespread use of wRVU-based compensation models for employed physicians and APPs.”

As the roll-out date for the new Fee Schedule grows closer, HSG is working with healthcare systems to help them gain an understanding of the potential impact on the network.  Then HSG works with the organization to build a model to address changes to wRVU targets and bonus conversion factors that yield productive compensation levels that are financially sustainable and uphold fair market value and commercial reasonableness. Coincident with the compensation impact review, HSG conducts a series of provider

Read more

Researchers Will Infect Healthy Volunteers with COVID to Test Potential Vaccines

Getty

The U.K. government has announced plans for a COVID-19 vaccine trial where healthy volunteers will be intentionally infected with the novel coronavirus.

The human challenge trial, led by scientists at Imperial College London, is scheduled to begin in January at a quarantine facility in London with 34 million pounds ($44 million) of funding from the British government, The New York Times and ABC News reported.

Volunteers will be vaccinated and then intentionally inhale a diluted dose of the virus while being closely monitored by scientists and doctors. The overall goal of the study is to test several vaccine candidates in a controlled environment.

Trial participants will include up to 90 healthy volunteers from 18 to 30 years old. They are including younger volunteers to minimize the risk of health complications. Once the volunteers have the virus, they will be monitored in a quarantine ward of the Royal Free Hospital. There, they will undergo daily, even hourly, tests over two to three weeks, the Washington Post reported.

Getty

RELATED: White House Blocks FDA’s Coronavirus Vaccine Guidelines, Plus Other Need-to-Knows

According to ABC News, Dr. Chris Chiu, from the Department of Infectious Disease at Imperial College London and lead researcher on the human challenge study, said that the human challenge trial will be able to determine within 10 weeks how effective a COVID-19 vaccine is.

The study is expected to be complete in 2021 and is still subject to ethical and regulatory approval, CNBC reported. Experts are divided on whether the study is ethical, since there is no highly effective treatment for Covid-19.

RELATED VIDEO: Donald and Melania Trump Test Positive for Coronavirus: ‘We Will Get Through This TOGETHER!’

Donald and Melania Trump Test Positive for Coronavirus: ‘We Will Get Through This TOGETHER!’

PLUS: Melania Trump Speaks Out After Being Diagnosed with COVID-19: ‘Please Be Sure You Are Staying Safe’

RELATED: Scientists Insist Herd Immunity Won’t Work to End COVID — in Opposition to Trump’s Claims

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, revealed last week that a coronavirus vaccine for the respiratory illness may be available next year.

“[A vaccine] will likely be [available] within the first quarter of 2021, by let’s say April of 2021,” he told CBS Evening News. “But that would be predicated on the fact that all of the vaccines that are in clinical trials have proven to be safe and effective.”

As information about the coronavirus pandemic rapidly changes, PEOPLE is committed to providing the most recent data in our coverage. Some of the information in this story may have changed after publication. For the latest on COVID-19, readers are encouraged to use online resources from CDC, WHO, and local public health departments. To help provide doctors and nurses on the front lines with life-saving medical resources, donate to Direct Relief here.

Source Article

Read more